Rifaximin treatment shapes a unique metagenome-metabolism network in patients with decompensated cirrhosis.

Mei-Tong NiePei-Qin WangPei-Mei ShiXia-Lu HongXin ZhangBaoyu XiangMenghui ZhangWei Fen Xie

Published in: Journal of gastroenterology and hepatology (2024)

Our study revealed distinct microbiome-metabolite networks regulated by rifaximin intervention in patients with decompensated cirrhosis. These findings suggest that targeting these specific metabolites or related bacteria might be a potential therapeutic strategy for decompensated cirrhosis.

Keyphrases

heart failure
ejection fraction
liver failure
randomized controlled trial
ms ms
single cell
drug delivery
replacement therapy
smoking cessation